港股医药ETF(159718)规模创近1月新高，医疗创新ETF(516820)获杠杆资金持续布局，多重利好催化有望推动创新药板块估值修复预期

Group 1: Market Performance - The CSI Hong Kong Stock Connect Healthcare Index (930965) decreased by 0.45% as of May 30, 2025, with mixed performance among constituent stocks [1] - Leading gainers included Yaoshi Bang (09885) up 8.11%, and CSPC Pharmaceutical Group (01093) up 6.56%, while Crystal International Holdings (02228) led the decline at 3.58% [1] - The Hong Kong Healthcare ETF (159718) fell by 0.39%, with a latest price of 0.76 yuan, but saw a 4.07% increase over the past week [1] Group 2: Liquidity and Trading Volume - The Hong Kong Healthcare ETF had a turnover rate of 11.78% with a trading volume of 30.169 million yuan, indicating active market participation [1] - The average daily trading volume for the Hong Kong Healthcare ETF over the past week was 60.5112 million yuan [1] Group 3: Innovation and Research Developments - The CSI Medical and Medical Device Innovation Index (931484) rose by 0.10% as of May 30, 2025, with notable gains from Jiutian Pharmaceutical (300705) up 4.20% and Yirui Technology (688301) up 3.42% [2] - The Medical Innovation ETF (516820) showed mixed performance, with a recent price of 0.36 yuan and a 1.72% increase over the past week [2] - The latest size of the Medical Innovation ETF reached 1.525 billion yuan, with significant leverage funding activity [3] Group 4: Key Research Achievements - A new obesity treatment drug, Masitide, led by a Chinese research team, was published in the New England Journal of Medicine, marking a significant milestone for China's metabolic drug research [3] - The 2025 ASCO conference highlighted 71 original research projects from Chinese pharmaceutical companies, indicating a rise in R&D capabilities [3] - Institutions are advised to focus on innovative drug companies and prescription drug leaders, with a long-term positive outlook on private medical service valuations [3] Group 5: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 profitable and growth-oriented companies, reflecting the overall performance of the sector [4] - The top ten weighted stocks in the CSI Medical and Medical Device Innovation Index account for 66.51% of the index [4] - The CSI Hong Kong Stock Connect Healthcare Index includes 50 liquid and large-cap healthcare companies, with the top ten weighted stocks representing 60.54% of the index [5]